No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1986 and headquartered in Ludhiana, India, IOL Chemicals and Pharmaceuticals Limited operates as a global manufacturer and supplier of diverse pharmaceutical and chemical products. Its pharmaceutical portfolio encompasses a wide array of active pharmaceutical ingredients (APIs), featuring prominent pain and fever relievers such as ibuprofen, ibuprofen lysinate, ibuprofen sodium, and dex-ibuprofen. The company also provides other crucial APIs, including metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, and fenofibrate. These compounds are integral to treatments addressing various conditions, such as inflammation, pain relief, fever reduction, diabetes, platelet aggregation, cholesterol management, seizures, gallstones, and gastric acid inhibition. In addition to pharmaceuticals, IOL supplies specialized industrial chemicals like ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid. These chemicals are widely utilized across numerous industries, including food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and as chemical intermediates.
www.iolcp.comNo one on the platform currently holds IOLCP.NS.
No tracked institution reports a position in IOLCP.NS as of their last filing.
No one on the platform has traded IOLCP.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.5% | 7.9% | 16.6% | — | — | — |
| Rev. Growth % | 12.1% | 3.6% | ||||
| Profit Margin % | 5.9% | 6.2% | 9.1% | |||
| Free Cash Flow Margin % | 1.7% | -1.2% | 5.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $27.4B | +19.1% | $7.50 | $7.50–$7.50 | — | 1 |
| 2028 | $31.5B | +15.0% | $9.70 | $9.70–$9.70 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| IOLCP.NSIOL Chemicals and Pharmaceuticals Limited | $179.52 | -7.61% | $52.7B | — |
| ALEMBICLTD.NSAlembic Limited | $100.51 | -3.66% | $25.8B | — |
| HIKAL.BOHikal Limited | $212.35 | -6.47% | $26.1B | — |
| HIKAL.NSHikal Limited | $212.22 | -5.66% | $26.2B | — |
| INDOCO.NSIndoco Remedies Limited | $241.39 | -8.22% | $22.2B | — |
| MOREPENLAB.BOMorepen Laboratories Limited | $106.25 | -8.37% | $58.3B | — |
| MOREPENLAB.NSMorepen Laboratories Limited | $106.22 | -8.26% | $58.2B | — |
Source: Financial Modeling Prep · peers by sector/industry